Nurix Therapeutics, Inc. NRIX
NASDAQ
| 08/31/2026 | 05/31/2026 | 02/28/2026 | 11/30/2025 | 08/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 736.20% | -106.00% | -54.70% | -33.60% | -76.53% |
| Total Depreciation and Amortization | -27.70% | -24.47% | -8.53% | 34.23% | 20.60% |
| Total Amortization of Deferred Charges | -- | -- | -- | -53.85% | -- |
| Total Other Non-Cash Items | 29.86% | 27.94% | 46.87% | 44.83% | 42.01% |
| Change in Net Operating Assets | 218.16% | 36.21% | 127.79% | -445.21% | 709.44% |
| Cash from Operations | 1,172.81% | -52.90% | -17.72% | -39.14% | -36.06% |
| Capital Expenditure | 48.65% | 27.63% | 70.01% | -143.75% | -15.51% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -38.00% | 27.99% | -523.12% | 103.95% | 380.04% |
| Cash from Investing | -37.43% | 30.07% | -584.96% | 100.25% | 336.54% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 346.67% | 1,000.00% | 1,256.08% | 17.70% | -97.48% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 346.67% | 1,000.00% | 1,256.08% | 17.70% | -97.48% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 11,435.73% | -142.07% | -415.73% | 1,438.59% | 67.57% |